With the significant time and cost invested in bringing an Oncology therapy to market, biopharma companies are constantly investing in enhancing decision-making and patient outcomes. While RECIST offers a standardized methodology for measuring therapy response in solid tumors, download this whitepaper where we discuss how purpose-built visualization can revolutionize tumor evaluation and streamline insight generation.